MetaCap

Arrowhead Pharmaceuticals (ARWR) vs Belite Bio (BLTE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Belite Bio (BLTE) has outperformed Arrowhead Pharmaceuticals (ARWR) over the past year, gaining 5.7% versus a gain of 2.3%. Arrowhead Pharmaceuticals is the larger company by market cap ($5.85 billion vs $5.17 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARWR+2.27%BLTE+5.66%
+128%+61%-6%
Nov 21, 20251 yearNov 20, 2026
ARWR+0.63%BLTE+1102.83%
+1818%+827%-164%
Apr 25, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARWR versus BLTE key metrics
MetricARWRBLTE
Share price$41.37$127.38
Market cap$5.85B$5.17B
1-day change-5.22%-15.65%
YTD return-37.69%-20.37%
1-year return+2.27%+5.66%
5-year return-42.56%—
EPS (TTM)$-5.11$-2.84
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$450.82M—
Revenue growth (YoY)-45.65%—
Net income (latest FY)$-724.21M$-77.61M
Operating margin-156.86%—
Net margin-160.64%—
52-week high$95.49$200.00
52-week low$40.43$115.41
Distance from 52-week high-56.68%-36.31%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+156.39%+82.92%
Average volume2.08M195.65K
Shares outstanding141.37M40.61M
Employees1,06241
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Arrowhead Pharmaceuticals

ARWR stock →

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,062 employees

About Belite Bio

BLTE stock →

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees

ARWR vs BLTE FAQ

Which is bigger, Arrowhead Pharmaceuticals or Belite Bio?

Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $5.85B compared with $5.17B for Belite Bio (BLTE).

Which stock has performed better over the past year, ARWR or BLTE?

BLTE returned +5.66% over the past 12 months, compared with +2.27% for ARWR (price return, excluding dividends). Past performance does not predict future results.

Are Arrowhead Pharmaceuticals and Belite Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons